BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 24403233)

  • 1. Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives.
    Buder K; Gesierich A; Gelbrich G; Goebeler M
    Cancer Med; 2013 Oct; 2(5):674-86. PubMed ID: 24403233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives.
    Comito F; Marchese PV; Ricci AD; Tober N; Peterle C; Sperandi F; Melotti B
    Future Oncol; 2021 Nov; 17(33):4583-4606. PubMed ID: 34431316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.
    Pelster MS; Gruschkus SK; Bassett R; Gombos DS; Shephard M; Posada L; Glover MS; Simien R; Diab A; Hwu P; Carter BW; Patel SP
    J Clin Oncol; 2021 Feb; 39(6):599-607. PubMed ID: 33125309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uveal melanoma.
    Spagnolo F; Caltabiano G; Queirolo P
    Cancer Treat Rev; 2012 Aug; 38(5):549-53. PubMed ID: 22270078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of evidence about effectiveness of treatments for metastatic uveal melanoma.
    Augsburger JJ; Corrêa ZM; Shaikh AH
    Trans Am Ophthalmol Soc; 2008; 106():128-35; discussion 135-7. PubMed ID: 19277228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
    Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D
    PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of metastatic uveal melanoma: review and recommendations.
    Albert DM; Niffenegger AS; Willson JK
    Surv Ophthalmol; 1992; 36(6):429-38. PubMed ID: 1589858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
    Bhatia S; Moon J; Margolin KA; Weber JS; Lao CD; Othus M; Aparicio AM; Ribas A; Sondak VK
    PLoS One; 2012; 7(11):e48787. PubMed ID: 23226204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
    Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
    Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review.
    Heppt MV; Steeb T; Schlager JG; Rosumeck S; Dressler C; Ruzicka T; Nast A; Berking C
    Cancer Treat Rev; 2017 Nov; 60():44-52. PubMed ID: 28881222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma.
    Minor DR; Kim KB; Tong RT; Wu MC; Kashani-Sabet M; Orloff M; Eschelman DJ; Gonsalves CF; Adamo RD; Anne PR; Luke JJ; Char D; Sato T
    Cancer Biother Radiopharm; 2022 Feb; 37(1):11-16. PubMed ID: 35021863
    [No Abstract]   [Full Text] [Related]  

  • 13. Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.
    Pföhler C; Cree IA; Ugurel S; Kuwert C; Haass N; Neuber K; Hengge U; Corrie PG; Zutt M; Tilgen W; Reinhold U
    Anticancer Drugs; 2003 Jun; 14(5):337-40. PubMed ID: 12782938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy.
    Itchins M; Ascierto PA; Menzies AM; Oatley M; Lo S; Douraghi-Zadeh D; Harrington T; Maher R; Grimaldi AM; Guminski A
    Melanoma Res; 2017 Jun; 27(3):243-250. PubMed ID: 28230715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent breakthroughs in metastatic uveal melanoma: a cause for optimism?
    Sacco JJ; Kalirai H; Kenyani J; Figueiredo CR; Coulson JM; Coupland SE
    Future Oncol; 2018 Jun; 14(14):1335-1338. PubMed ID: 29741103
    [No Abstract]   [Full Text] [Related]  

  • 16. The treatment of metastatic uveal melanoma.
    Pyrhönen S
    Eur J Cancer; 1998 Jul; 34 Suppl 3():S27-30. PubMed ID: 9849406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
    Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
    Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ; Mabaera R; Shirai K
    J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
    Piulats JM; Espinosa E; de la Cruz Merino L; Varela M; Alonso Carrión L; Martín-Algarra S; López Castro R; Curiel T; Rodríguez-Abreu D; Redrado M; Gomà M; Rullán AJ; Calvo González A; Berrocal-Jaime A
    J Clin Oncol; 2021 Feb; 39(6):586-598. PubMed ID: 33417511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.